A rapid test kit for simultaneous detection of sulfonamides, florfenicol, tilmicosin and trimethoprim in pork

By designing a rapid detection kit and using diluents and monoclonal antibodies for enzyme label detection, the problem of long-term detection of veterinary drugs in pork in the prior art was solved, and a rapid, sensitive and economical detection effect was achieved.

CN113341148BActive Publication Date: 2024-11-01NEW HOPE LIUHE +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110627678.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-06-05
Publication Date
2024-11-01
Estimated Expiration
2041-06-05

AI Technical Summary

Technical Problem

The existing veterinary drug residue detection methods for sulfonamide, frefenicol, temicocin and trimethoprim in pork require a large amount of samples and a long test time, which cannot meet the rapid monitoring needs of pigs before entering the factory.

Method used

Provide a rapid detection kit, including reaction solution A, reaction solution B, negative control solution, concentrated cleaning agent, color developer and stopping agent. Through the design of premixed orifice plate and reaction orifice plate, these in pork can be detected simultaneously. Veterinary drug residues are detected by diluents and monoclonal antibodies for enzyme labels to simplify the operation process.

Benefits of technology

It realizes rapid detection of sulfonamides, frefenicol, temicocin and trimethoprim in pork, meets the needs of high-throughput detection, has high sensitivity and strong specificity, and shortens the detection time to within 30 minutes, saving costs. More than half.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure QLYQS_1
    Figure QLYQS_1
Patent Text Reader

Abstract

The present invention provides a rapid detection kit for simultaneously detecting sulfonamides, florfenicol, tilmicosin and trimethoprim in pork, and belongs to the technical field of veterinary drug residue analysis and detection. The kit provided by the present invention can simultaneously and efficiently and accurately detect whether pork contains sulfonamides, florfenicol, tilmicosin and trimethoprim, and effectively solves the problems of long ELISA reaction time and low sensitivity of colloidal gold.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of veterinary drug residue analysis and detection, and in particular relates to a rapid detection kit for simultaneously detecting sulfonamides, florfenicol, tilmicosin and trimethoprim in pork. Background Art

[0002] With the development of my country's social economy and the continuous increase in the income of urban and rural residents, people's living standards have been greatly improved. At present, the per capita pork consumption of Chinese people has reached the international average level. However, while the output of pork products has increased significantly, food safety issues such as veterinary drugs, feed additives, illegal additives and other harmful substances have become the focus and hot spot of widespread social concern.

[0003] At present, the existing detection methods for sulfonamide, florfenicol, tilmicosin and trimethoprim veterinary drug residues in China are mainly instrumental analysis, enzyme-linked immunosorbent assay (ELISA) and colloidal gold immunochromatography. However, these traditional methods have the disadvantages of large sample volume requirements and long detection time, so they cannot meet the monitoring of veterinary drug residues before pigs enter the factory. Summary of the invention

[0004] The object of the present invention is to provide a rapid detection kit for simultaneously detecting sulfonamides, florfenicol, tilmicosin and trimethoprim in pork.

[0005] To achieve the above-mentioned purpose, the present invention provides a rapid detection kit for simultaneously detecting sulfonamide, florfenicol, tilmicosin and trimethoprim in pork, the kit comprising the following components: reaction solution A, reaction solution B, negative control solution, concentrated cleaning agent, color developer A, color developer B, stop agent, premixed well plate, reaction well plate.

[0006] Preferably, the reaction solution A is a mixed working solution of sulfonamide, florfenicol, tilmicosin, and trimethoprim monoclonal antibody;

[0007] Preferably, the mixed working solution is obtained by diluting the reaction solution A diluent;

[0008] The formula of the diluent of the reaction solution A per 1000 ml is: 100 ml 0.5 M EDTA, 900 ml 0.02 M borate buffer, 0.05% cyclodextrin, 0.05% caseinate sodium, 0.10% Triton X-100, 0.05% sodium azide, 0.10% trehalose, 0.05% polyethylene glycol, 0.05% polyacrylamide, and 0.05% whey protein.

[0009] Preferably, the dilution multiples of sulfonamide, florfenicol, tilmicosin and trimethoprim monoclonal antibody in the mixed working solution are: sulfonamide 1 / 25W, florfenicol 1 / 8W, tilmicosin 1 / 6.8W, trimethoprim 1 / 30W.

[0010] Preferably, the antigen preparation method of the florfenicol monoclonal antibody is as follows:

[0011] A. Hapten synthesis

[0012] (1) Weigh 500 mg of florfenicol original drug, add 6 ml of pyridine, stir until completely dissolved, add 153 mg of HS, heat to 60 degrees, and when TLC shows no change in the reaction, spin dry the pyridine, dissolve it with methanol, add silica gel to mix the sample, spin dry the sample for column chromatography, collect the desired solution, spin dry, and obtain 450.2 mg of florfenicol hapten;

[0013] B. Immunogen Preparation

[0014] (1) Dissolve 17.08 mg of florfenicol hapten in 1.5 ml of DMF, add 25.75 mg of EDC, and dissolve 15.46 mg of NHS, and activate by stirring at room temperature for 2-3 hours to obtain a florfenicol immunogen reaction solution;

[0015] (2) Weigh 50 mg of BSA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath and stir. Add the florfenicol immunogen reaction solution dropwise and stir for 24 hours.

[0016] (3) placing the reaction product of step (2) into a dialysis bag, stirring and dialyzing at 4°C for 3 days with 2L 0.01M PBS, and centrifuging the dialyzed product to obtain the florfenicol immunogen;

[0017] C. Preparation of coating material

[0018] (1) Dissolve 17.08 mg of florfenicol hapten in 1.5 ml of DMF, add 25.75 mg of EDC, and dissolve 15.46 mg of NHS, and activate by stirring at room temperature for 2-3 hours to obtain a florfenicol coating reaction solution;

[0019] (2) Weigh 33.6 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath and stir. Add the florfenicol coating reaction solution dropwise and stir for 24 hours.

[0020] (3) The reaction product of step (2) was placed in a dialysis bag, and dialyzed with 2L 0.01M PBS at 4°C for 3 days with stirring. The dialyzed product was centrifuged to obtain the florfenicol coating source;

[0021] The structural formula of the florfenicol hapten is:

[0022]

[0023] The antigen preparation method of the sulfonamide monoclonal antibody is as follows:

[0024] A. Hapten synthesis

[0025] (1) Weigh 500 mg of sodium hydroxide and dissolve it in 6 ml of water in an ice bath. Weigh 600 mg of aminobenzoic acid and add it to the solution. Stir. Add 700 mg of acetanilide sulfonyl chloride in batches and monitor the reaction by spotting the plate.

[0026] (2) After the reaction, the pH value was adjusted to 2, and the viscous material was dissolved in ethanol after precipitation, and recrystallized with 70% ethanol. The crystallization was cooled overnight and filtered to obtain 580 mg of the intermediate;

[0027] (3) dissolving 580 mg of the intermediate in 8 ml of methanol, adding 5 ml of hydrochloric acid, and monitoring the reaction by spot plate. After the reaction is complete, adding sodium hydroxide solution to adjust the pH value to 7, extracting, and spin drying the collected solution to obtain 480 mg of sulfonamide hapten;

[0028] B. Immunogen Preparation

[0029] (1) Dissolve 5.55 mg of sulfonamide hapten in 1.5 ml of DMF, add 0.98 mg of HCl, and dissolve 4.5 mg of NaNO2, and activate by stirring at room temperature for 2-3 hours to obtain a sulfonamide immunogen reaction solution;

[0030] (2) Weigh 20 mg of BTG and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath. Add the sulfonamide immunogen reaction solution dropwise while stirring. Stir and react for 24 h.

[0031] (3) placing the reaction product of step (2) into a clean dialysis bag, adding 2 L of 0.01 M PBS, and dialyzing at 4° C. for 3 days with stirring, and centrifuging the dialyzed product to obtain the sulfonamide immunogen;

[0032] C. Preparation of coating material

[0033] (1) Dissolve 20.6 mg of sulfonamide hapten in 1.5 ml of DMF, add 3.65 mg of HCl and 16.8 mg of NaNO2 to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain a sulfonamide coating reaction solution;

[0034] (2) Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution until it is fully dissolved. Cool it to 0-4°C in an ice bath, add the sulfonamide coating reaction solution dropwise while stirring, and react with stirring for 24 h.

[0035] (3) The reaction product of step (2) was placed in a dialysis bag rinsed with distilled water, and dialyzed with 2L of 0.01M PBS at 4°C for 3 days with stirring. The dialyzed product was centrifuged to obtain the sulfonamide coating source;

[0036] The structural formula of the sulfonamide hapten is:

[0037]

[0038] The antigen preparation method of the trimethoprim monoclonal antibody is as follows:

[0039] A. Immunogen Preparation

[0040] (1) Dissolve 5.19 mg of trimethoprim raw material in 1.5 ml of DMF, add 10.3 mg of EDC and 6.18 mg of NHS to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain a trimethoprim immunogen reaction solution;

[0041] (2) Weigh 20 mg of KLH and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath. Add the trimethoprim immunogen reaction solution dropwise while stirring. Stir and react for 24 h.

[0042] (3) placing the reaction product of step (2) into a dialysis bag, dialyzing with 2L of 0.01M PBS at 4°C for 3 days with stirring, and centrifuging the dialyzed product to obtain the trimethoprim immunogen;

[0043] B. Preparation of coating material

[0044] (1) Dissolve 19.3 mg of trimethoprim raw material in 1.5 ml of DMF, add 38.34 mg of EDC and 23.02 mg of NHS, and activate by stirring at room temperature for 2-3 hours to obtain a trimethoprim coating reaction solution;

[0045] (2) Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath. Add the trimethoprim coating reaction solution dropwise while stirring. Stir and react for 24 h.

[0046] (3) The reaction product was placed in a dialysis bag, and dialyzed with 2 L of 0.01 M PBS at 4 °C for 3 days with stirring. The dialyzed product was centrifuged to obtain the trimethoprim coating source;

[0047] The antigen preparation method of the tilmicosin monoclonal antibody is as follows:

[0048] A. Immunogen Preparation

[0049] (1) Dissolve 15.56 mg of tilmicosin raw material in 1.5 ml of DMF, add 3.05 mg of CDI to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain a tilmicosin immunogen reaction solution;

[0050] (2) Weigh 20 mg of KLH and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution, cool it to 0-4°C in an ice bath, add the tilmicosin immunogen dropwise while stirring, and stir for 24 hours;

[0051] (3) The reaction product of step (2) was placed in a dialysis bag, 2 L of 0.01 M PBS, and dialyzed at 4° C. for 3 days with stirring, and the dialyzed product was centrifuged to obtain the tilmicosin immunogen;

[0052] B. Preparation of coating material

[0053] (1) Dissolve 57.9 mg of tilmicosin raw material in 1.5 ml of DMF, add 11.34 mg of CDI to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain a tilmicosin coating reaction solution;

[0054] (2) Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath. Add the tilmicosin coating reaction solution dropwise while stirring. Stir and react for 24 h.

[0055] (3) The reaction product of step (2) was placed in a dialysis bag, and dialyzed with 2 L of 0.01 M PBS at 4° C. for 3 days with stirring. The dialyzed product was centrifuged to obtain the Tilmicosin coating precursor.

[0056] 6. The kit according to claim 1, characterized in that the reaction solution B is an enzyme label working solution obtained by diluting the enzyme-labeled secondary antibody with a reaction solution B diluent.

[0057] 7. The kit according to claim 6, characterized in that the formula of the diluent of reaction solution B per 1100 ml is: 300 ml fetal bovine serum, 750 ml 0.02 mol / L borate buffer, 50 ml isopropanol, 5 / W allura red, 0.10% sodium azide, 0.05% casein, 0.05% trehalose, and 0.05% sucrose.

[0058] 8. The kit according to claim 1, characterized in that the negative control solution is 0.01 mol / L pH 7.4 PBS buffer;

[0059] The concentrated cleaning agent is a 0.01 mol / L pH 7.4 PBS buffer solution containing 2% Tween 20 and 0.05% Proclin 300;

[0060] The developer A is a mixed aqueous solution containing 0.1% carbamide peroxide, 0.5% sodium acetate, 0.5‰ light stabilizer, and 0.2‰ polyvinyl alcohol;

[0061] The developer B is a mixed aqueous solution containing 0.2% N,N-dimethylformamide, 0.3% formic acid, 0.5% tetramethylbenzidine, 0.5‰ light stabilizer, and 0.1% cyclodextrin;

[0062] The stop agent is a mixed aqueous solution containing 0.05% sulfuric acid and 0.2% sodium dodecyl sulfate.

[0063] 9. The kit according to claim 1, characterized in that the premixed well plate is a 96-well 2 ml deep well plate, and the reaction well plate is a reaction well plate with 4 8-wells x 12 strips;

[0064] The processing method of the reaction well plate is as follows: 100 μL of 10 μg / mL sulfonamide, florfenicol, tilmicosin and trimethoprim coating source are added to different reaction well plates respectively, incubated at 37° C. for 2 hours, the coating solution is poured off, and the plates are washed with a 20-fold diluted washing solution. After drying, 150 μL of blocking solution is added to each well, and the plates are incubated at 37° C. for 1 hour. The liquid in the wells is poured off, and the reaction well plates coated with the coating source are obtained after drying, and the plates are vacuum-sealed with aluminum film for storage;

[0065] The coating buffer is: 0.03 mol / L carbonate buffer with pH 9.6;

[0066] The blocking solution is: a 0.2 mol / L pH 7.7 phosphate buffer solution containing 50 g / L sucrose, 2.5 g / L casein, 0.5% calf serum, and 3‰ sodium azide.

[0067] 10. The kit according to any one of claims 1 to 9, characterized in that the detection steps when using the kit to detect each 20 mg pork sample are as follows:

[0068] (1) Take about 20 mg of sample, add 300 μl of PBS buffer, vortex for 10 seconds and then test to obtain the sample solution;

[0069] (2) Take out the premixed well plate, add 50ul of negative control solution to each well of the negative control, add 50ul of sample solution to each well of the experimental group, then add 100ul of reaction solution A and then 20ul of reaction solution B, react at room temperature for 1 min to obtain the premixed solution;

[0070] (3) Transfer 100 μl of the premixed solution to each well of the reaction plate and react at low temperature for 10 min;

[0071] (4) Discard the liquid in the reaction well plate and add 260 μl of concentrated detergent diluted 20 times with water to each well for thorough washing;

[0072] (5) Discard the liquid in the reaction well plate, invert it on absorbent paper to dry, add 50ul of color developer A and color developer B to each well, and react at room temperature for 5 minutes;

[0073] (6) After the reaction is completed, add 50 μl of stop agent to each well and mix thoroughly. After reacting for 5 min, read the absorbance at 450 nm / 630 nm.

[0074] (7) Judgment criteria: When the sample OD value is greater than the cut-off value, the result is judged as negative;

[0075] When the sample OD value is less than or equal to the cut off value, the result is judged as positive;

[0076] Cut off value = negative control OD value × project binding rate; project binding rate = average binding rate of 20 samples + 3 times standard deviation; binding rate = sample absorbance value / negative control absorbance value × 100%.

[0077] The beneficial effects of the present invention are:

[0078] The kit of the present invention can detect sulfonamides, florfenicol, tilmicosin and trimethoprim in pork at the same time, and can effectively solve the problems of relatively long ELISA reaction time and low sensitivity of colloidal gold. Moreover, the kit of the present invention can detect 98 samples at the same time, meeting the demand for high-throughput detection on site; it has high sensitivity, a low detection limit and strong specificity; it is simple to operate and saves time, and the whole detection time only takes less than 30 minutes, while the time required for the general ELISA method to detect a single drug is more than 60 minutes; compared with traditional ELISA products, the cost can be saved by more than half. BRIEF DESCRIPTION OF THE DRAWINGS

[0079] Figure 1 Kit sensitivity test 1-7 sample measurement chart;

[0080] Figure 2 Kit specific detection 1-7 sample measurement diagram. DETAILED DESCRIPTION

[0081] In order to clearly illustrate the technical features of this solution, this solution is described below through a specific implementation method.

[0082] Example 1 Synthesis of Florfenicol Artificial Antigen

[0083] 1. Structural modification of florfenicol hapten

[0084] (1) Rinse a 50 ml round-bottom flask, blow dry it with ethanol, fix it on a stirrer, and add a stir bar;

[0085] (2) Weigh 500 mg of florfenicol original drug, add 6 ml of pyridine, stir until completely dissolved, keep a sample, add 153 mg of HS, heat to 60 degrees, and when TLC shows no change in the reaction, treat, spin dry pyridine, dissolve with methanol, add silica gel to mix the sample, spin dry the sample for column chromatography, collect the required solution, spin dry, and obtain 450.2 mg of florfenicol hapten;

[0086] The structural formula of florfenicol hapten is:

[0087]

[0088] 2. Preparation of Florfenicol Immunogen

[0089] (1) Dissolve 17.08 mg of florfenicol hapten in 1.5 ml of DMF, add 25.75 mg of EDC and 15.46 mg of NHS, and stir at room temperature for 2-3 hours to obtain reaction solution 1;

[0090] (2) Weigh 50 mg of BSA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution to fully dissolve it. Cool it to 0-4°C in an ice bath, add reaction solution 1 dropwise under stirring at 1000 rpm, and stir for 24 h.

[0091] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L of 0.01 M PBS at 4°C for 3 days with stirring (100 rpm). The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min, and dispensed into 1.5 ml / tubes. The antigens were numbered and stored at -20°C for later use.

[0092] 3. Preparation of Florfenicol Coating

[0093] (1) Dissolve 17.08 mg of florfenicol hapten in 1.5 ml of DMF, add 25.75 mg of EDC and 15.46 mg of NHS, and stir at room temperature for 2-3 hours to obtain reaction solution 1;

[0094] (2) Weigh 33.6 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution to fully dissolve it. Cool it to 0-4°C in an ice bath, add the reaction solution of step 1 dropwise under stirring at 1000 rpm, and react at 500 rpm for 24 h;

[0095] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L of 0.01 M PBS at 4°C for 3 days with stirring (100 rpm). The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min, and dispensed into 1.5 ml / tubes. The antigens were numbered and stored at -20°C for later use.

[0096] Example 2 Synthesis of sulfonamide artificial antigen

[0097] 1. Structural modification of sulfonamide hapten

[0098] (1) Weigh 500 mg of sodium hydroxide and dissolve it in 6 ml of water under ice bath, weigh 600 mg of aminobenzoic acid and add it, stir, add 700 mg of acetanilide sulfonyl chloride in batches, and monitor the reaction by spot plate;

[0099] (2) After the reaction, the pH was adjusted to about 2, and a viscous substance was precipitated. It was dissolved in ethanol, recrystallized from 70% ethanol, cooled and crystallized overnight, and filtered to obtain 580 mg of the intermediate;

[0100] (3) Dissolve 580 mg of the intermediate in 8 ml of methanol, add 5 ml of hydrochloric acid, monitor the reaction by spot plate, and after the reaction is complete, add sodium hydroxide solution to adjust the pH to 7, extract, and spin dry the collected solution to obtain 430 mg of sulfonamide hapten;

[0101] The structural formula of sulfonamide hapten is:

[0102]

[0103] 2. Preparation of sulfonamide immunogen

[0104] (1) Dissolve 5.55 mg of sulfonamide hapten in 1.5 ml of DMF, stir at 200 rpm for 10 min, add 0.98 mg of HCl and 4.5 mg of NaNO2, and stir at room temperature for 2-3 h to obtain reaction solution 1;

[0105] (2) Weigh 20 mg of BTG and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Stir at 200 rpm for 10 min to fully dissolve it. Cool it to 0-4°C in an ice bath. Add reaction solution 1 dropwise under stirring at 1000 rpm. Stir and react at 500 rpm for 24 h.

[0106] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L 0.01 M PBS at 4°C with stirring (100 rpm) for 3 days. The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min to obtain the sulfonamide immunogen, which was divided into 1.5 ml / tube and stored at -20°C for later use.

[0107] 3. Preparation of sulfonamide coating

[0108] (1) Dissolve 20.6 mg of sulfonamide hapten in 1.5 ml of DMF, stir at 200 rpm for 10 min, add 3.65 mg of HCl and 16.8 mg of NaNO2 to dissolve, stir at room temperature for 2-3 h, and obtain reaction solution 1;

[0109] (2) Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Stir at 200 rpm for 10 min to fully dissolve it. Cool it to 0-4°C in an ice bath. Add reaction solution 1 dropwise under stirring at 1000 rpm. Stir and react at 500 rpm for 24 h.

[0110] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L of 0.01 M PBS at 4°C for 3 days with stirring (100 rpm). The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min to obtain the sulfonamide coating product, which was divided into 1.5 ml / tube and stored at -20°C for future use.

[0111] Example 3 Synthesis of trimethoprim-sulfamethoxazole artificial antigen

[0112] 1. Preparation of Trimethoprim Immunogen

[0113] (1) Dissolve 5.19 mg of trimethoprim raw material in 1.5 ml of DMF, stir at 200 rpm for 10 min, add 10.3 mg of EDC and 6.18 mg of NHS, stir at room temperature (500 rpm) for 2-3 h to activate, and obtain reaction solution 1;

[0114] (2) Weigh 20 mg of KLH and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Stir at 200 rpm for 10 min to fully dissolve it. Cool the mixture to 0-4°C in an ice bath. Add reaction solution 1 dropwise under stirring at 1000 rpm and react at 500 rpm for 24 h.

[0115] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L of 0.01 M PBS at 4°C for 3 days with stirring (100 rpm). The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min to obtain the trimethoprim immunogen, which was packaged in 1.5 ml / tube and stored at -20°C for future use.

[0116] 2. Preparation of coating material

[0117] (1) 19.3 mg of trimethoprim raw material was dissolved in 1.5 ml of DMF, stirred at 200 rpm for 10 min, 38.34 mg of EDC and 23.02 mg of NHS were added and dissolved, and stirred at room temperature (500 rpm) for activation for 2-3 h to obtain reaction solution 1;

[0118] (2) Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Stir at 200 rpm for 10 min to fully dissolve it. Cool it to 0-4°C in an ice bath. Add the reaction solution from step 1 dropwise under stirring at 1000 rpm. Stir and react at 500 rpm for 24 h.

[0119] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L of 0.01 M PBS at 4 °C with stirring (100 rpm) for 3 days. The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min, divided into 1.5 ml / tubes, and stored at -20 °C for later use.

[0120] Example 4 Synthesis of Tilmicosin Antigen

[0121] 1. Preparation of Tilmicosin Immunogen

[0122] (1) 15.56 mg of tilmicosin raw material was dissolved in 1.5 ml of DMF, stirred at 200 rpm for 10 min, 3.05 mg of CDI was added and dissolved, and stirred at room temperature (500 rpm) for activation for 2-3 h to obtain reaction solution 1;

[0123] (2) Weigh 20 mg of KLH and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Stir at 200 rpm for 10 min to fully dissolve it. Cool it to 0-4°C in an ice bath. Add the reaction solution from step 1 dropwise under stirring at 1000 rpm. Stir and react at 500 rpm for 24 h.

[0124] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L 0.01 M PBS at 4 °C for 3 days with stirring (100 rpm). The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min to obtain the tilmicosin immunogen, which was packaged in 1.5 ml / tube and stored at -20 °C for future use;

[0125] 2. Preparation of Tilmicosin Coating

[0126] (1) 57.9 mg of tilmicosin raw material was dissolved in 1.5 ml of DMF, stirred at 200 rpm for 10 min, 11.34 mg of CDI was added to dissolve, and stirred at room temperature (500 rpm) for activation for 2-3 h to obtain reaction solution 1;

[0127] (2) Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Stir at 200 rpm for 10 min to fully dissolve it. Cool it to 0-4°C in an ice bath. Add the reaction solution from step 1 dropwise under stirring at 1000 rpm. Stir and react at 500 rpm for 24 h.

[0128] (3) The reaction product was placed in a dialysis bag (10 cm) rinsed with distilled water, and dialyzed with 2 L of 0.01 M PBS at 4°C for 3 days with stirring (100 rpm). The solution was changed 3 times a day (once in the morning, once in the afternoon and once in the evening), for a total of 9 changes. The dialyzed product was centrifuged at 5000 rpm for 6 min to obtain the Tilmicosin coating material, which was divided into 1.5 ml / tube and stored at -20°C for future use.

[0129] Example 5 Monoclonal Antibody Preparation

[0130] 1. Animal immunization

[0131] (1) The immunogen prepared in Example 1-4 was dissolved in physiological saline at a rate of 100 μg / mouse, and mixed with equal volumes of Freund's complete adjuvant, and then injected subcutaneously at the back of the neck to immunize 6-8 week old female Balb / c mice;

[0132] (2) On the 7th, 14th and 28th days after the initial immunization, the immunogen was mixed with an equal volume of Freund's incomplete adjuvant and boosted for each immunization. Three days before fusion, a booster immunization was performed with 100 μg of immune complex per mouse without Freund's adjuvant.

[0133] 2. Cell fusion and cloning

[0134] (1) According to the conventional method, spleen cells of immunized mice were mixed with mouse myeloma cells (SP2 / 0) in the logarithmic growth phase, and then preheated fusion agent (PEG4000) was slowly added within 45 seconds for fusion, and evenly suspended with HAT medium, and then an appropriate amount of feeder cells were added and cultured in a 96-well culture plate at 37°C in a 5% CO2 incubator. After 5 days, half of the medium was replaced with HT medium, and the whole medium was replaced after 9 days.

[0135] (2) After cell fusion, when the cells grow to 1 / 4 of the culture well area, hybridoma cells are screened by step-by-step screening. The indirect ELISA method is used for the initial screening. The ELISA plate is coated with the coating antigen (its optimal coating concentration and positive serum dilution are pre-titrated by the square array method), the culture supernatant of the well to be tested is added, incubated, washed, and then sheep anti-mouse IgG-HRP and IgM-HRP are added, and OPD is used for color development.

[0136] (3) The positive wells screened were then screened using the indirect competitive ELISA method. First, the cell supernatant was mixed with an equal volume of 100 μg / mL of the drug to be tested, incubated in a 37°C water bath for 30 min, and then added to the coated ELISA plate. At the same time, PBS was used instead of the drug to be tested as a control, and the rest of the steps were the same as above.

[0137] (4) If the OD value after blocking with the test drug drops below 50% of the control well, it is judged as positive. The wells that are positive after 2-3 tests are immediately subcloned using the limiting dilution method.

[0138] 3. Preparation and purification of monoclonal antibodies

[0139] The hybridoma cells established after 2-3 subcloning were expanded and cultured, and the supernatant was collected to determine the titer by indirect ELISA and frozen; 8-10 week-old Balb / c mice were intraperitoneally injected with 0.5 mL of liquid paraffin per mouse, and 7-10 days later, 1-2×10 hybridoma cells were intraperitoneally injected 5 / mouse, and the ascites of the mice were extracted after 7-10 days. The cell supernatant or ascites was collected, purified by the caprylic acid-saturated ammonium sulfate method, and stored in a -20°C environment after purification to obtain florfenicol, sulfonamide, trimethoprim, and tilmicosin monoclonal antibodies.

[0140] Sulfonamide, florfenicol, tilmicosin, trimethoprim and other drugs with similar structures or functions were serially diluted and operated by indirect ELISA method to determine their standard curves, and the 50% inhibition concentration (IC50) of each was found on the curve. The cross-reaction rate of sulfonamide, florfenicol, tilmicosin, trimethoprim and each analogue was calculated by the following formula:

[0141] Table 1 Florfenicol cross-reactivity rate

[0142] Competitor Cross-reaction rate Florfenicol 100% Florfenicolamide 96% Thiamphenicol 11.1% Chloramphenicol <0.1%

[0143] It can be seen from Table 1 that the florfenicol monoclonal antibody prepared in the present invention has excellent specificity for florfenicol and florfenicol amide.

[0144] Table 2 Cross-reaction rate of sulfonamide drugs

[0145]

[0146]

[0147] As can be seen from Table 2, the sulfonamide monoclonal antibody prepared by the present invention has excellent specificity for sulfamethoxazole, sulfadimethoxine, sulfadimethoxine, sulfadimethoxine, sulfamethoxypyridazine, sulfamethoxazole, sulfamethoxazole, sulfadimethoxine, sulfadimethoxine and sulfadimethoxine.

[0148] Table 3 Trimethoprim cross-reactivity rate

[0149] Competitor Cross-reaction rate Trimethoprim (TMP) 100% Trimethoprim (DVD) <0.1%

[0150] It can be seen from Table 3 that the methicillin monoclonal antibody prepared in the present invention has excellent specificity for methicillin.

[0151] Table 4 Tilmicosin cross-reaction rate

[0152] Competitor Cross-reaction rate Tilmicosin 100% Tylosin 1.2% Erythromycin <0.1% Lincomycin <0.1%

[0153] It can be seen from Table 5 that the tilmicosin monoclonal antibody prepared in the present invention has excellent specificity for tilmicosin.

[0154] Example 6

[0155] A rapid test kit for simultaneous detection of sulfonamides, florfenicol, tilmicosin and trimethoprim in pork

[0156] (1) The kit is composed of:

[0157] 4 reaction plates: sulfonamide, florfenicol, tilmicosin, and trimethoprim reaction plates (8 wells × 12 strips for each); premixed plate: (96-well 2mL deep-well plate); negative control: 1 bottle (12mL); reaction solution A: 1 bottle (50mL); reaction solution B: 1 bottle (25mL); concentrated detergent: 1 bottle (20×, 100mL / bottle); 1 bottle each of color developer A and color developer B (70mL / bottle); stop agent: 1 bottle (70mL / bottle).

[0158] (2) The processing method of the reaction well plate is:

[0159] Use coating buffer to dilute sulfonamide, florfenicol, tilmicosin and trimethoprim antigens to 10.0 μg / mL, add 100 μL of coating source to each well, incubate at 37°C for 2 h, pour off the coating solution, wash twice with 20-fold diluted washing solution, 30 seconds each time, pat dry, then add 150 μL of blocking solution to each well, incubate at 37°C for 1 h, pour off the liquid in the wells, dry to obtain the reaction well plate coated with coating source, and store it in a vacuum seal with aluminum film.

[0160] The coating buffer is: 0.03 mol / L carbonate buffer at pH 9.6;

[0161] The blocking solution is: 0.2 mol / L pH 7.7 phosphate buffer solution containing 50 g / L sucrose, 2.5 g / L casein, 0.5% calf serum, and 3‰ sodium azide.

[0162] (3) The negative control solution was 0.01 mol / L pH 7.4 PBS buffer.

[0163] (4) Reaction solution A is a monoclonal antibody mixed working solution obtained by diluting the monoclonal antibodies of sulfonamides, florfenicol, tilmicosin, and trimethoprim with the diluent of reaction solution A by a corresponding multiple;

[0164] The dilution multiples of each monoclonal antibody in the mixed working solution are: sulfonamide 1 / 25W, florfenicol 1 / 8W, tilmicosin 1 / 6.8W, and trimethoprim 1 / 30W.

[0165] (5) The formula of the reaction solution A dilution is:

[0166]

[0167]

[0168] (6) Reaction solution B is: the enzyme labeling working solution obtained by diluting the enzyme-labeled secondary antibody with the reaction solution B diluent.

[0169] The dilution of the reaction solution B is:

[0170] Fetal bovine serum 300ml 0.02mol / L borate buffer 750ml Isopropyl alcohol 50ml Temptation Red 5 / W Sodium Azide 0.10% Casein 0.05% Trehalose 0.05% sucrose 0.05%

[0171] (7) The concentrated cleaning agent is: 0.01 mol / L pH 7.4 PBS buffer containing 2% Tween 20 and 0.05% Proclin 300.

[0172] (8) Color developer A is a mixed aqueous solution containing 0.1% carbamide peroxide, 0.5% sodium acetate, 0.5‰ light stabilizer, and 0.2‰ polyvinyl alcohol.

[0173] (9) The stop agent is a mixed aqueous solution of 0.05% sulfuric acid and 0.2% sodium dodecyl sulfate.

[0174] Example 7

[0175] Method for using a rapid detection kit for simultaneously detecting sulfonamides, florfenicol, tilmicosin and trimethoprim in pork

[0176] Sample pretreatment: 20 mg of sample was pricked, 300 μl of PBS buffer was added, and the sample was vortexed for 10 s before detection.

[0177] (1) According to the number of samples to be tested, place the reaction plates for each project on the plate rack in a certain order in advance, mark them, and record the positions of each negative control and sample for future use. A 96-well plate can test up to 95 samples at a time, and the number of reaction plate wells can be increased or decreased according to the actual number of samples.

[0178] (2) Take out the premixed well plate, mark and record the corresponding positions of the negative control and each sample. Take 50 μL of negative control and sample, add 100 μL of reaction solution A to each well, then add 20 μL of reaction solution B, gently pipette 5-10 times with an 8-channel pipette, and pre-react at room temperature (23℃-27℃) for 1 minute.

[0179] (3) Transfer 100 μL of the premixed solution to the corresponding reaction well plate and react at low temperature for 10 min.

[0180] (4) Pour out the liquid in the well plate and add 260 μl of concentrated detergent diluted 20 times with water to each well for thorough washing. Wash thoroughly 3-4 times, soaking for 15-30 seconds each time.

[0181] (5) Pour out the liquid in the well plate, place the reaction plate upside down on absorbent paper, and pat dry.

[0182] (6) Immediately add 50 μl of chromogen A and 50 μl of chromogen B to each well and react at room temperature for 5 min.

[0183] (7) Remove the cover film, add 50 μL of stop agent to each well of the plate, and mix thoroughly.

[0184] (8) Within 5 minutes after termination, read the absorbance of the ELISA plate at dual wavelengths of 450 nm and 630 nm using an ELISA reader.

[0185] (9) Judgment criteria: When the sample OD value is greater than the cut-off value, it is judged as negative; when the sample OD value is less than or equal to the cut-off value, it is judged as positive.

[0186] Cut off value = negative control OD value × binding rate of each item

[0187] Item binding rate = average binding rate of 20 samples + 3 times standard deviation

[0188] Binding rate = sample absorbance value / negative control absorbance value × 100%

[0189] Example 8 Differences in the binding rates of various items between the diluent of the reaction solution A provided by the present invention and the diluent of the reaction solution A configured with a conventional formula

[0190] The conventional formula of reaction solution A dilution is:

[0191] 0.5M EDTA 100ml 0.02M borate buffer 900ml Cyclodextrin 0.05% Sodium Caseinate 0.05% Triton X-100 0.10% Sodium Azide 0.05% Trehalose 0.10%

[0192] (2) using the reaction solution A dilution provided by the present invention and the reaction solution A dilution prepared by a conventional formula for detection;

[0193] The binding rates of each item in the dilution of reaction solution A prepared in the conventional formula are as follows:

[0194] project Sulfonamides Florfenicol Tilmicosin Trimethoprim Binding rate (%) 25% 60% 70% 55%

[0195] The combination rates of each item under the diluent of the reaction solution A provided by the present invention are as follows:

[0196] project Sulfonamides Florfenicol Tilmicosin Trimethoprim Binding rate (%) 25% 25% 20% 25%

[0197] Example 9 Difference in stability between the diluent of reaction solution B provided by the present invention and the diluent of reaction solution B prepared by conventional formula

[0198] The conventional formula of reaction solution B dilution is:

[0199] Fetal bovine serum 300ml 0.02mol / L borate buffer 750ml Isopropyl alcohol 50ml Temptation Red 5 / W Sodium Azide 0.10% Trehalose 0.05%

[0200] (1) The conventionally formulated reaction solution B dilution and the reaction solution B dilution in the kit of the present invention were stored at 37° C. and taken out at 0, 1, 3, 6, 9, 12, 15, and 30 days to detect the negative control;

[0201] The stability results of the dilution of reaction solution B prepared by conventional formula are as follows:

[0202] Days (d) Sulfonamides (OD) Florfenicol(OD) Tilmicosin (OD) Trimethoprim(OD) 0 0.88 1.05 1.11 0.94 1 0.83 0.93 1.03 0.89 3 0.57 0.49 0.56 0.40 6 0.33 0.32 0.39 0.33 9 0.22 0.18 0.24 0.26

[0203] The stability results of the dilution of reaction solution B of the present invention are as follows:

[0204]

[0205]

[0206] It can be seen that the stability of the dilution of the reaction solution B of the present invention did not decrease when stored for 30 days, while the stability of the dilution of the reaction solution B configured with the conventional formula became poor after 9 days.

[0207] Example 10

[0208] The combination rate of the kit of the present invention for sulfonamides, florfenicol, tilmicosin and trimethoprim

[0209] (1) Blank pork samples (negative by LC-MS / MS) were added with different concentrations of reference substances to the desired concentration (the detection level of the target drug).

[0210] (2) Measure the blank spiked sample, take the absorbance values ​​of 20 spiked samples / negative control absorbance values, calculate the average value, and add 3 times the standard deviation to obtain the item binding rate. The results are as follows:

[0211]

[0212]

[0213] To avoid false negative results, the item combination rate of the present invention is adjusted upward according to the calculated value. Therefore, the optimal item combination rates of the kit of the present invention are: sulfonamide 25%, florfenicol 20%, tilmicosin 10%, trimethoprim 30%, and the corresponding added concentrations are the lowest detection levels that can be achieved by the target drugs.

[0214] Embodiment 11

[0215] The sensitivity detection of the kit of the present invention

[0216] The sensitivity of the present invention refers to the percentage of the number of positive samples detected by the kit of the present invention with positive results to the total number of positive samples at the actual minimum detection level.

[0217] (1) 50 positive added pork samples were tested using the kit of the present invention, with the added concentration being the minimum detection level of the target drug, and the testing was performed according to the testing steps of Example 7;

[0218] (2) Count the number of positives and calculate the sensitivity according to the following formula: Sensitivity = number of positives / 50 × 100%. The results of the detection are shown in the following table and Figure 1 Shown

[0219]

[0220]

[0221] It can be seen from the above results that all sample test results are positive results, therefore, the sensitivity of the kit of the present invention is 100%.

[0222] Example 12

[0223] Specific detection of the kit of the present invention

[0224] The specificity of the present invention refers to the percentage of negative samples detected by the kit of the present invention with negative results when the experimental conditions reach the minimum detection level.

[0225] (1) 50 negative pork samples were tested using the kit of the present invention according to the testing steps of Example 7;

[0226] (2) Count the number of negatives and calculate the specificity according to the following formula: Specificity = number of negatives / 50 × 100%. The results of the detection are shown in the following table and Figure 2 shown.

[0227]

[0228]

[0229]

[0230] The above results show that all samples were negative, so the specificity of this kit is 100%.

[0231] False positive rate of the test kit in Example 13

[0232] The false positive rate refers to the maximum probability (in percentage) of detecting a positive result in a negative sample when the kit of the present invention reaches the actual minimum detection level. The calculated result is the maximum false positive rate of the kit of the present invention.

[0233] The results of Example 10 were statistically analyzed, and the false positive rate was calculated according to the following formula: false positive rate = number of false positives / 50 × 100%, and it was concluded that the false positive rate of the kit of the present invention was 0.

[0234] False negative rate of the test kit in Example 14

[0235] The false negative rate refers to the maximum probability (in percentage) of detecting a negative result in a positive sample when the kit of the present invention reaches the actual minimum detection level. The calculation result is the maximum false negative rate of the kit of the present invention.

[0236] The results of Example 9 were statistically analyzed and the false negative rate was calculated according to the following formula: false negative rate = number of false negatives / 50 × 100%, and it was concluded that the false negative rate of the kit of the present invention was 0.

[0237] Technical features not described in the present invention can be achieved through or by adopting existing technologies and will not be described in detail here. Of course, the above description is not a limitation of the present invention, and the present invention is not limited to the above examples. Changes, modifications, additions or substitutions made by ordinary technicians in this technical field within the essential scope of the present invention should also fall within the scope of protection of the present invention.

Claims

1. A rapid test kit for simultaneously detecting sulfonamide, florfenicol, tilmicosin and trimethoprim in pork, characterized in that: The kit comprises the following components: reaction solution A, reaction solution B, negative control solution, concentrated cleaning agent, color developer A, color developer B, stop agent, premixed well plate and reaction well plate; The reaction solution A is a mixed working solution of sulfonamide monoclonal antibody, florfenicol monoclonal antibody, tilmicosin monoclonal antibody and trimethoprim monoclonal antibody; The mixed working solution is obtained by diluting the reaction solution A diluent; The formula of the diluent of the reaction solution A per 1000 ml is: 100 ml 0.5 M EDTA, 900 ml 0.02 M borate buffer, 0.05% cyclodextrin, 0.05% sodium caseinate, 0.10% Triton X-100, 0.05% sodium azide, 0.10% trehalose, 0.05% polyethylene glycol, 0.05% polyacrylamide and 0.05% whey protein; The dilution multiples of the sulfonamide monoclonal antibody, florfenicol monoclonal antibody, tilmicosin monoclonal antibody and trimethoprim monoclonal antibody in the mixed working solution are: sulfonamide monoclonal antibody 1 / 25W, florfenicol monoclonal antibody 1 / 8W, tilmicosin monoclonal antibody 1 / 6.8W and trimethoprim monoclonal antibody 1 / 30W; The antigen preparation method of the florfenicol monoclonal antibody is as follows: A. Hapten synthesis (1) Weigh 500 mg of florfenicol original drug, add 6 ml of pyridine, stir until completely dissolved, add 153 mg of HS, heat to 60 degrees, and when TLC shows no change in the reaction, spin dry the pyridine, dissolve it in methanol, add silica gel to mix the sample, spin dry the sample for column chromatography, collect the required solution, spin dry, and obtain 450.2 mg of florfenicol hapten; B. Immunogen Preparation (1) Dissolve 17.08 mg of florfenicol hapten in 1.5 ml of DMF, add 25.75 mg of EDC and 15.46 mg of NHS, and activate by stirring at room temperature for 2-3 hours to obtain a florfenicol immunogen reaction solution; (2) Weigh 50 mg of BSA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath and stir. Add the florfenicol immunogen reaction solution dropwise and stir for 24 hours. (3) The reaction product of step (2) was placed in a dialysis bag, and dialyzed with 2 L of 0.01 M PBS at 4 °C for 3 days with stirring. The dialyzed product was centrifuged to obtain the florfenicol immunogen; C. Preparation of coating material (1) Dissolve 17.08 mg of florfenicol hapten in 1.5 ml of DMF, add 25.75 mg of EDC and 15.46 mg of NHS, and activate by stirring at room temperature for 2-3 hours to obtain a florfenicol coating reaction solution; (2) Weigh 33.6 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath and stir. Add the original florfenicol coating reaction solution dropwise and stir for 24 hours. (3) The reaction product of step (2) was placed in a dialysis bag, and dialyzed with 2 L of 0.01 M PBS at 4° C. for 3 days under stirring. The dialyzed product was centrifuged to obtain the florfenicol coating source; The structural formula of the florfenicol hapten is: ; The antigen preparation method of the sulfonamide monoclonal antibody is as follows: a. Hapten synthesis ① Weigh 500 mg of sodium hydroxide, dissolve it in 6 ml of water in an ice bath, weigh 600 mg of aminobenzoic acid, add it, stir, add 700 mg of acetanilide sulfonyl chloride in batches, and monitor the reaction by spot plate; ② After the reaction, the pH value was adjusted to 2, and the viscous material was dissolved in ethanol after precipitation, and recrystallized from 70% ethanol, cooled and crystallized overnight, and filtered to obtain 580 mg of the intermediate; ③ Dissolve 580 mg of the intermediate in 8 ml of methanol, add 5 ml of hydrochloric acid, monitor the reaction with a spot plate, and after the reaction is complete, add sodium hydroxide solution to adjust the pH value to 7, extract, and spin dry the collected solution to obtain 430 mg of sulfonamide hapten; b. Immunogen Preparation ① Dissolve 5.55 mg of sulfonamide hapten in 1.5 ml of DMF, add 0.98 mg of HCl and 4.5 mg of NaNO2 to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain a sulfonamide immunogen reaction solution; ② Weigh 20 mg of BTG and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath. Add the sulfonamide immunogen reaction solution dropwise while stirring. Stir and react for 24 hours. ③ Place the reaction product of step ② into a clean dialysis bag, add 2L 0.01M PBS, and dialyze at 4°C for 3 days with stirring. Centrifuge the dialyzed product to obtain the sulfonamide immunogen; c. Preparation of coating material ① Dissolve 20.6 mg of sulfonamide hapten in 1.5 ml of DMF, add 3.65 mg of HCl and 16.8 mg of NaNO2 to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain the sulfonamide coating reaction solution; ② Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution to fully dissolve it. Cool it to 0-4°C in an ice bath. Add the sulfonamide coating reaction solution dropwise while stirring. Stir and react for 24 hours. ③ Place the reaction product of step ② into a dialysis bag rinsed with distilled water, add 2L 0.01M PBS, stir and dialyze at 4°C for 3 days, centrifuge the dialyzed product to obtain the sulfonamide coating source; The structural formula of the sulfonamide hapten is: ; The antigen preparation method of the trimethoprim monoclonal antibody is as follows: (A) Immunogen preparation 1) Dissolve 5.19 mg of trimethoprim raw material in 1.5 ml of DMF, add 10.3 mg of EDC and 6.18 mg of NHS, and activate by stirring at room temperature for 2-3 hours to obtain a trimethoprim immunogen reaction solution; 2) Weigh 20 mg of KLH and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath. Add the trimethoprim immunogen reaction solution dropwise while stirring. Stir and react for 24 hours. 3) The reaction product of step 2) was placed in a dialysis bag, and dialyzed with 2L 0.01M PBS at 4°C for 3 days with stirring, and the dialyzed product was centrifuged to obtain the trimethoprim immunogen; (B) Preparation of coating material 1) Dissolve 19.3 mg of trimethoprim raw material in 1.5 ml of DMF, add 38.34 mg of EDC and 23.02 mg of NHS to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain a trimethoprim coating reaction solution; 2) Weigh 50 mg of OVA and dissolve it in 3.5 ml of 0.1 M sodium bicarbonate solution. Cool it to 0-4°C in an ice bath. Add the trimethoprim coating reaction solution dropwise while stirring. Stir and react for 24 hours. 3) The reaction product was placed in a dialysis bag, and dialyzed with 2L 0.01M PBS at 4°C for 3 days with stirring. The dialyzed product was centrifuged to obtain the trimethoprim coating source; The antigen preparation method of the tilmicosin monoclonal antibody is as follows: (a) Immunogen preparation I. Dissolve 15.56 mg of tilmicosin raw material in 1.5 ml of DMF, add 3.05 mg of CDI to dissolve, and activate with stirring at room temperature for 2-3 hours to obtain a tilmicosin immunogen reaction solution; Ⅱ. Weigh 20 mg KLH and dissolve it in 3.5 ml 0.1 M sodium bicarbonate solution, cool it to 0-4°C in an ice bath, add tilmicosin immunogen dropwise under stirring, and react for 24 hours; III. The reaction product of step II was placed in a dialysis bag, and dialyzed with 2L 0.01M PBS at 4°C for 3 days with stirring. The dialyzed product was centrifuged to obtain the tilmicosin immunogen; (b) Preparation of coating material I. Dissolve 57.9 mg of tilmicosin raw material in 1.5 ml of DMF, add 11.34 mg of CDI to dissolve, and activate by stirring at room temperature for 2-3 hours to obtain a tilmicosin coating reaction solution; Ⅱ. Weigh 50 mg OVA and dissolve it in 3.5 ml 0.1 M sodium bicarbonate solution, cool it to 0-4°C in an ice bath, add the Tilmicosin coating reaction solution dropwise while stirring, and stir for 24 hours; III. The reaction product of step II was placed in a dialysis bag, 2L 0.01M PBS, and dialyzed at 4°C for 3 days with stirring. The dialyzed product was centrifuged to obtain the Tilmicosin coating original; The reaction solution B is an enzyme-labeled working solution obtained by diluting the enzyme-labeled secondary antibody with the reaction solution B diluent; The formula of the diluent of reaction solution B per 1100 ml is: 300 ml fetal bovine serum, 750 ml 0.02 mol / L borate buffer, 50 ml isopropanol, 5 / W allura red, 0.10% sodium azide, 0.05% casein, 0.05% trehalose and 0.05% sucrose; The negative control solution is 0.01 mol / L pH 7.4 PBS buffer; The concentrated cleaning agent is 0.01 mol / L pH 7.4 PBS buffer containing 2% Tween 20 and 0.05% Proclin 300; The developer A is a mixed aqueous solution containing 0.1% carbamide peroxide, 0.5% sodium acetate, 0.5‰ light stabilizer and 0.2‰ polyvinyl alcohol; The developer B is a mixed aqueous solution containing 0.2% N,N-dimethylformamide, 0.3% formic acid, 0.5% tetramethylbenzidine, 0.5‰ light stabilizer and 0.1% cyclodextrin; The stop agent is a mixed aqueous solution containing 0.05% sulfuric acid and 0.2% sodium lauryl sulfate; The reaction well plate is processed as follows: 100 μL of 10 μg / mL sulfonamide, florfenicol, tilmicosin and trimethoprim coating agents are added to different reaction well plates respectively, incubated at 37° C. for 2 h, the coating solution is removed, and the plates are washed with a 20-fold diluted washing solution. After drying, 150 μL of blocking solution is added to each well, the plates are incubated at 37° C. for 1 h, the liquid in the wells is removed, and the reaction well plates coated with the coating agents are obtained after drying, and the plates are vacuum sealed with aluminum film for storage; The coating buffer is: 0.03 mol / L carbonate buffer with pH 9.6; The blocking solution is: 0.2 mol / L pH 7.7 phosphate buffer solution containing 50 g / L sucrose, 2.5 g / L casein, 0.5% calf serum and 3‰ sodium azide.

2. The kit according to claim 1, characterized in that The detection steps for each 20 mg pork sample using the kit are as follows: a) Take about 20 mg of sample, add 300 μl of PBS buffer, vortex for 10 seconds and then test to obtain sample solution; b) Take out the premixed well plate, add 50ul of negative control solution to each well of the negative control, add 50ul of sample solution to each well of the experimental group, then add 100ul of reaction solution A, then add 20ul of reaction solution B, react at room temperature for 1min to obtain the premixed solution; c) transferring 100ul of the premixed solution to each well of the reaction plate and reacting at low temperature for 10min; d) Discard the liquid in the reaction well plate and add 260ul of concentrated detergent diluted 20 times with water to each well for thorough washing; e) Discard the liquid in the reaction well plate, invert it on absorbent paper to dry, add 50ul of color developer A and color developer B to each well, and react at room temperature for 5 minutes; f) After the reaction is completed, add 50ul of stop agent to each well and mix thoroughly. After reacting for 5 minutes, read the absorbance at 450nm / 630nm. g) Judgment criteria: When the sample OD value is greater than the cut off value, the result is judged as negative; When the sample OD value is less than or equal to the cut off value, the result is judged as positive; Cut off value = negative control OD value × project binding rate; Project binding rate = average binding rate of 20 samples + 3 times standard deviation; binding rate = sample absorbance value / negative control absorbance value × 100%.